Recombinant-follicle stimulating hormone is more effective than urinary human menopausal gonadotropin in ovarian hyperstimulation for assisted reproductive technology treatment

• NAKAGAWA KOJI

  Division of Reproductive Medicine, Department of Perinetal Medicine and Maternal Care, National Center for Child Health and Development

• OHGI SHIREI

  Division of Reproductive Medicine, Department of Perinetal Medicine and Maternal Care, National Center for Child Health and Development

• KOJIMA RIEKO

  Division of Reproductive Medicine, Department of Perinetal Medicine and Maternal Care, National Center for Child Health and Development

• SUGAWARA KANA

  Division of Reproductive Medicine, Department of Perinetal Medicine and Maternal Care, National Center for Child Health and Development

• HORIKAWA TAKASHI

  Division of Reproductive Medicine, Department of Perinetal Medicine and Maternal Care, National Center for Child Health and Development

• ITO MEGUMU

  Division of Reproductive Medicine, Department of Perinetal Medicine and Maternal Care, National Center for Child Health and Development

• IRAHARA MINOARU

  Department of Obstetrics and Gynecology, School of Medicine, the University of Tokushima

• SAITO HIDEKAZU

  Division of Reproductive Medicine, Department of Perinetal Medicine and Maternal Care, National Center for Child Health and Development

収録刊行物

• Reproductive medicine and biology

  Reproductive medicine and biology 6 (1), 27-32, 2007-03-01

キーワード

• assisted reproductive technology
• ovarian stimulation
• recombinant-follicle stimulating hormone
• urinary hMG

詳細情報

• CRID: 1573387450169697920
• NII論文ID: 10018849591
• NII書誌ID: AA11706516
• ISSN: 14455781
• Web Site: https://search.jamas.or.jp/link/ui/2007294574
• 本文言語コード: en
• データソース種別:
  • CiNii Articles